New Fasenra® Data from the Meltemi Extension Trial Confirm Long-term Safety and Efficacy in Severe Eosinophilic Asthma for up to Five Years

At least 75% of FASENRA-treated patients with elevated blood eosinophil levels had zero exacerbations each year of the open-label period.

    • Tags:

Nice Insight

Nice Insight, established in 2010, is the research division of That’s Nice, A Science Agency, providing data and analysis from proprietary annual surveys, custom primary qualitative and quantitative research as well as extensive secondary research. Current annual surveys include The Nice Insight Contract Development & Manufacturing (CDMO/CMO), Survey The Nice Insight Contract Research - Preclinical and Clinical (CRO) Survey, The Nice Insight Pharmaceutical Equipment Survey, and The Nice Insight Pharmaceutical Excipients Survey.

Q: